

## Review

# Current concepts in human prion protein (Prp) misfolding, *Prnp* gene polymorphisms and their contribution to Creutzfeldt-Jakob Disease (CJD)

K. Michalczyk and M. Ziman

School of Exercise, Biomedical and Health Science, Edith Cowan University, Joondalup, Western Australia, Australia

**Summary.** Transmissible spongiform encephalopathies are a group of neural degenerative diseases that may be infectious, sporadic, or hereditary and are associated with an abnormally folded prion protein. Unfortunately at the current time it is not at all clear what the normal structure of the prion protein actually is or how it is toxic to cells.

Extensive research on prion diseases has led to a dramatic increase in understanding of the pathogenesis of prion disorders, which will hopefully lead to the development of effective treatments. The inability to detect the disease in blood using current technology has made screening difficult. While fortunately there has been a decline in the number of clinical cases of transmissible variant CJD, evidence indicates that very long incubation periods can occur in humans so there may be a long slow, gradual epidemic. In particular, clinical cases in genotypes other than those homozygous for methionine at codon 129 of PRNP have not yet occurred, but such cases might be expected to have longer incubation periods and show differences in pathology to those seen to date.

Transgenic animal studies have shown that a large proportion of infected animals develop sub-clinical disease. Moreover, results from a large prevalence study in humans show that several cases test positive but do not develop clinical disease. It is possible therefore that further cases of secondary transmission could occur by iatrogenic spread, which could result in vCJD persisting in the UK at low levels for many years, highlighting the importance of continued vigilance.

**Key words:** Prion diseases, *PRNP* gene, Creutzfeldt Jakob disease (CJD)

## Introduction

Creutzfeldt-Jakob disease (CJD), first described by Creutzfeldt and Jakob in the 1920s, is a rare, fatal brain disorder associated with the presence of a misshapen protein known as a prion protein. The term prion was derived from the words "proteinaceous infectious particle" in 1982 by Nobel Prize winner, Stanley B. Prusiner.

CJD belongs to transmissible spongiform encephalopathies (TSE's), a group of progressive neurodegenerative conditions that include Creutzfeldt-Jakob Disease (CJD), variant Creutzfeldt-Jakob Disease (vCJD), Gerstmann-Sträussler-Scheinker disease (GSS), Fatal Familial Insomnia (FFI), Kuru- in humans and Scrapie in sheep, Bovine Spongiform Encephalopathy (BSE) or "Mad Cow Disease" in cows, transmissible mink encephalopathy (TME), and chronic wasting disease (CWD) in mule deer and elk. TSE may be infectious, sporadic, or hereditary (Hilton, 2006).

CJD occurs worldwide at a rate of about 1 case per million people per year. From 10 to 15 percent of CJD cases are inherited as an autosomal dominant disorder. Familial Creutzfeldt-Jakob disease occurs in unusually high frequency in Chileans (Masters et al., 1979) and is particularly high amongst Libyan Jews (Kahana et al., 1974). The disease usually develops in a person between the ages of 55 and 65 years. In more than 85 percent of cases, the duration of CJD is less than 1 year (median: 4 months) after onset of symptoms (Knight and Will, 2004).

The sporadic form of the disease accounts for around 80 percent of people who develop CJD world-wide (Hilton, 2006). The sporadic disease presents in patients as a rapidly progressive dementia. In the majority of cases the length of the illness is under six months in contrast to other prion diseases which generally have a longer duration. Clinical features of CJD include a neurological presentation, with dementia, and a progressive cerebellar syndrome including ataxia, gait,

and speech abnormalities and seizures. In most patients, these symptoms are followed by involuntary movements and the appearance of a typical diagnostic electroencephalogram tracing (Knight and Will, 2004).

Variant CJD (vCJD) was first described in 1996 in the United Kingdom. Epidemiologic and laboratory evidence indicate that vCJD in humans is caused by transmission of the agent causing BSE in cattle via consumption of BSE-contaminated cattle products (Brown et al., 2001; Belay and Schonberger, 2002). The variant form of CJD has several different characteristics (Brown et al., 2001; Belay and Schonberger, 2002); the median age at death for vCJD patients is 28 years, compared with 68 years for patients with classic CJD. In addition, all vCJD cases have neuropathologic findings distinctly different from those of classic CJD (Ironside, 1998), and all have had a particular genetic profile i.e., homozygosity for methionine at codon 129 of the prion protein gene (Will et al., 2004). Thus, cases of vCJD can be distinguished from classic CJD on the basis of clinical, genetic and pathologic data.

The diagnosis of prion diseases, especially CJD is difficult because the clinical symptoms are nonspecific and sometimes variable. Moreover, imaging, EEG and other laboratory tests are not unequivocal. Neuropathological studies are needed but their interpretation may be ambiguous. Transmissible spongiform encephalopathies (TSEs) are characterised by neurodegenerative processes with characteristic spongiosis. However, vacuolization similar to that in TSE-spongiosis may occur in some CNS disorders or in putrescent brain tissue. In some cases of CJD, particularly those of long duration, neuronal loss and astrocyte proliferation can mask the presence of spongiform changes, especially when vacuoles are not numerous. The only certain diagnostic marker for TSE is the presence of PrP<sup>Sc</sup>, the misfolded prion protein that is believed to be the direct cause of all TSEs (Zaborowski, 2004).

### The human prion protein gene (PRNP)

The human gene (*PRNP*) that encodes the prion protein (PrP) was first identified in scrapie-infected rodents. It is a single-copy chromosomal gene and the protein is encoded from a single exon. In addition to the protein-coding exon (exon 3), PrP genes in mammals contain one (humans) or two (sheep and mice) 5' noncoding exons that are included in the final mRNA (Lee et al., 1998) (Fig. 1). Further upstream, the promoter region of the human PRNP gene is a well characterized region that is highly GC-rich, lacks a canonical TATA box, contains a CCAAT box, and has a number of putative binding sites for transcription factors SP1, AP1 and AP2 (Mahal et al., 2001).

### The structure of the PRNP gene and mRNA

The nucleotide sequence of human *PRNP*,

determined from cosmid clone pGPRP1 (Puckett et al., 1991), is 35,522bp in length. The gene has two known exons (134 and 2355 nucleotides in length) separated by an intron of 12,696 bases, and a dG + dC content of 44.1%. A 1-kb region around exon 1 forms a "CpG island" (Fig. 1) (Lee et al., 1998), as found 5' of the transcriptional start site of many housekeeping genes.

There are also two repeats in the human *PRNP* gene locus (MER74 and MER88; Fig. 2) that are related to two consensus sequences in the human repeat database (MER73 and MER54) (characteristic of viral LTRs (Long Terminal Repeats), having TG...CA terminal dinucleotides flanked by 5-bp insertion site duplications (Smit and Riggs, 1995).

In fact, a large percentage of the human *PRNP* locus appears to be derived from mobile elements; there are several short interspersed repetitive element (SINE), and long interspersed repetitive element (LINE) insertions in the PRNP gene (Smit, 1996; Smit et al., 1996). Interestingly, 14 of the 15 SINEs (*Alu* sequences) belong to subfamilies (*AluSx*, *AluJ*, and monomers) thought to be >35 million years old (Smit and Riggs, 1995; Kapitonov and Jurka, 1996).

From a comparison of human, sheep and mouse *PRNP/Prp* genes, it is clear that there are common sites of integration of known classes of transposable elements or processed pseudogenes (Fig. 2). Insertion of these elements since the mammalian radiation has increased the size of the human PRNP locus by 20% and both the mouse and sheep loci by 41% although some large deletions have partially reversed this size increase. In almost all cases, repetitive sequences belonging to subfamilies predicted to predate the mammalian radiation are found at orthologous sites in all species, whereas predicted younger elements are generally found in only one species.

The exonic structure of the human gene differs from that of other mammals. While the first exon and the beginning of intron 1 are poorly conserved, there is a highly conserved region of 99-bp present in human DNA, 2303 bp after exon 1. This region is 82% and 81% identical to exon 2 of sheep and mouse, respectively (Fig. 3) (Lee et al., 1998). However this gene region does not appear to be encoded in humans as it is not present in any human PRNP mRNAs analyzed to date even though this human exon 2-like sequence is flanked by consensus splice donor and acceptor sites similar (but not identical) to those in the mouse and sheep genes. Also, since the exon 2-like sequence does not contain a translation start codon (ATG) in the correct translational reading frame with human PRNP exon 3, it forms part of the UTR of human RNA.

All human *PRNP* cDNAs isolated to date have exon 1 spliced directly to exon 3 (using the exon numbering system of the sheep and mouse *PrP* genes). It is possible that nucleotide substitutions at the *donor* splice site in the human gene (as indicated in Fig. 3B) are responsible for the absence of exon 2 since the *acceptor* splice site is typical and highly conserved. The conservation of the

## Prion protein misfoldign and Creutzfeldt-Jakob disease (CJD)


first half of exon 2 in the human sequence is possibly caused by the presence of transcription factor binding sites at this locus. Baybutt and Manson (1997) have shown that the last 550 bp of intron 1 is important for promoter activity of the mouse PrP gene, and it is possible that this functional region extends into exon 2 (Lee et al., 1998).

Alternatively, the human exon 2 could be included within a subset of mRNAs from tissues that have not yet been analyzed. This possibility is compatible with observed tissue specific alternate exon 2 splicing of *PrP* in other mammals; exon 2-containing transcripts have been described in cattle (Yoshimoto et al., 1992) and in the Syrian hamster (SHa) *PrP* gene, for which exon 1

originally appeared directly spliced to exon 3 (Basler et al., 1986). Whereas 90% of brain SHaPrP mRNAs exhibit exon 1-3 splicing, 10% include exon 2 sequences similar to those of sheep and mouse (Li and Bolton, 1997). Interestingly, an increased abundance of exon 2-containing mRNAs was observed in brain mRNA of scrapie-infected hamsters, which may reflect preferential expression in astrocytes (which become activated during the course of prion infections).

### The PrPc protein


The normal prion protein, PrPc, encoded by exon 3 of the prion gene (PRNP), is produced in prion diseases,



**Fig. 1. A.** The human *PRNP* gene is located on chromosome: 20; Maps: 20pter-p12 (NCBI Entrez Gene). **B.** Structure of the *PrP* gene and its mRNA. Exons are shown in light blue and the coding region (entirely contained in exon 3) is shown in dark blue (NCBI Entrez Gene). **C.** A summary of features found at PrP loci. (A) The human PrP locus. (B) The sheep PrP locus. (C) The mouse locus (Prnp (A-C) (1) The positions of the exons in each species. The scale is in kb. (2) The frequency of observed CpG dinucleotides divided by frequency of expected CpG. An unusually high CpG frequency is found in the promoter region of each PrP gene. The mouse PrP gene has a second high CpG region in intron 2 (3) Simple repeats at least 10 nucleotides in length (derived from Lee et al., 1998).


The normal PrPc protein is a glycoprotein that is attached to the plasma membrane by a glycosyl phosphatidylinositol anchor (Prusiner, 1998). It is present in cells of the central nervous system (Kretzschmar et al., 1986; Stahl et al., 1987, 1990) and

in muscle cells (Brown et al., 1998). In neurons prion protein is mainly localized at synaptic terminals, in cholesterol-rich microdomains of the plasma membrane known as caveolae (Prusiner, 1998). PrPc is composed of approximately 250 residues, and is proteolytically processed to remove a 22-residue N-terminal signal peptide and a 23 C-terminal amino acid segment after addition of the glycosyl phosphatidylinositol (GPI) anchor to Ser-231 (Prusiner, 1996, 1997). Molecular modeling studies indicate that PrPc contains several  $\alpha$ -helical regions of secondary structure (Gasset et al., 1992; Huang et al., 1994). The processed protein contains a 179-214 disulfide crosslink and glycosylation sites at Asn-181 and Asn-197. A protease resistant core present between residues 90-231, is sufficient to transmit



**Fig. 2.** Comparison of the human, sheep, and mouse PRNP/PrP loci. The complete sheep and human sequences are shown, whereas the Prp mouse cosmid sequence extends 2.5 kb upstream of the aligned regions. Deletions in the genome >250 bp are indicated by brackets. Identified interspersed repeats are represented by four differently shaded arrows for the four major classes of repeats: SINEs, LINEs, LTR elements, and DNA transposons. Wide arrows are used for elements that are absent at the orthologous sites in the other two species and thus probably integrated after the mammalian radiation. Older elements are indicated with thinner arrows. The indicated shared interspersed repeats are usually not detectable in the mouse genome (and sometimes not in the sheep genome) by direct comparison with the repeat consensus sequence but could be inferred from the alignment with human DNA. A measure of similarity between the human and either sheep or mouse sequences, depicted by a graph above and below the human sequence, respectively. Regions outside the coding region that are conserved between all species are indicated with an asterisk (\*) (derived from Lee et al., 1998).

The GPI anchor signal sequence, the attachment of the GPI anchor and membrane anchorage of PrPc are all necessary for the terminal processing of glycans. However, complex glycosylation is not specific for GPI-anchored PrP; PrP-CD4 in which PrP is fixed to the membrane via the heterologous CD4 transmembrane domain is complex-glycosylated as well. In the absence of a membrane anchor, terminal glycosylation does not take place indicating that membrane anchoring provides a specialized environment (i.e. the membrane surface



may be necessary for native folding of PrP<sup>c</sup> (Pekari and Schmidt, 2003).

### PrP<sup>c</sup> protein misfolding

The pathogenic form of the protein is referred to as PrP<sup>Sc</sup> (PrP Scrapie) or PrP<sup>Res</sup> (protease resistant protein). The conversion of PrP<sup>c</sup>→PrP<sup>Sc</sup>, the pathogenic form, is a late post-translational process, occurring after PrP<sup>c</sup> has reached its normal cellular location. In contrast to PrP<sup>c</sup> which is largely  $\alpha$ -helical, PrP<sup>Sc</sup> is characterized by a high content of  $\beta$ -sheet structures (Caughey et al., 1991a,b; Gasset et al., 1993), partial resistance to proteolytic digestion, and a propensity to aggregate into insoluble amyloid-like fibrils and plaques (Prusiner, 1998; Torrent et al., 2003, 2004).

The exact mechanism of conversion of PrP<sup>c</sup> into PrP<sup>Sc</sup> is unclear; however, it is clear that PrP<sup>Sc</sup> autocatalyses the process (Kocisko et al., 1994). Two mechanisms of propagation have been suggested. One model advocates template-directed refolding (Aguzzi et al., 2001), whereby exogenously introduced PrP<sup>Sc</sup> interacts with PrP<sup>c</sup> to cause a conformational change of PrP<sup>c</sup> into PrP<sup>Sc</sup>, overcoming a high energy barrier that would normally prevent the spontaneous conversion. The second proposed mechanism, 'seeding' or 'nucleation polymerization', suggests that PrP<sup>Sc</sup> and PrP<sup>c</sup> are in a thermodynamic equilibrium from which PrP<sup>Sc</sup> can be recruited to a more stable crystal-like 'seed' composed of several precursor PrP<sup>Sc</sup> molecules (Jarrett and Lansbury, 1993). Studies in transgenic mice indicate that a protein chaperone facilitates the conversion of PrP<sup>Sc</sup> from PrP<sup>c</sup> (Telling et al., 1995).

Recent studies using highly purified PrP<sup>Sc</sup> have demonstrated its ability to transmit disease (Castilla et al., 2005), lending strong support to the 'protein-only' hypothesis of transmission. Furthermore the presence of

PrP<sup>Sc</sup> correlates with disease transmission and endogenous PrP<sup>c</sup> is a requirement for the development of the disease (Brandner et al., 1996a,b) which can be decreased with anti-PrP antibodies (Gabizon et al., 1988). Changes in neural electrophysiology seen in PrP-knockout mice (Collinge et al., 1994; Manson et al., 1995) are similar to those seen in scrapie-infected mice (Jefferys et al., 1994), in keeping with a 'loss of function' effect. However, in vitro, neural toxicity does not always correlate with conversion to PrP<sup>Sc</sup> and the mechanism by which PrP<sup>Sc</sup> causes neurodegeneration is unclear (Ma et al., 2002).

### Covalent reaction of the intramolecular disulfide bond of PrP<sup>c</sup> to form PrP<sup>Sc</sup>

PrP<sup>c</sup>→PrP<sup>Sc</sup> conversion is proposed to involve disulfide polymerization, by which the terminal thiolate group of a PrP<sup>Sc</sup> polymer attacks the *intramolecular* disulfide bond of a PrP<sup>c</sup> monomer, so that an intermolecular disulfide bond is formed, thus lengthening the PrP<sup>Sc</sup> polymer while maintaining a terminal thiolate group (Welker et al., 2001). The initial thiolate attack is facilitated by the experimentally observed association of the PrP<sup>c</sup> monomer and PrP<sup>Sc</sup> polymer (Horiuchi and Caughey, 1999; Horiuchi et al., 2000), which may destabilize the tertiary structure and the intramolecular PrP<sup>c</sup> disulfide bond. The subsequent conformational transition to the  $\beta$ -enriched scrapie isoform evidently protects the intermolecular disulfide bond (Muramoto et al., 1996; Herrmann and Caughey, 1998), inhibiting the back-reaction of depolymerization. Thus, in this model, the smallest infectious unit is an oligomer of PrP<sup>Sc</sup> that protects its intermolecular disulfide bond(s) from thiolate attack and has at least one free thiolate at which the PrP<sup>c</sup>→PrP<sup>Sc</sup> conversion can occur (Welker et al., 2001).




Fig. 4. Possible pathways for the formation of PrP<sup>Sc</sup> via an intermediate state that is critical for prion formation (derived from Kelly, 1998).

### A proposed mechanism for protein conformational change

Kelly (1998) proposed that formation of a weak dimer of PrPc (90-231), which can occur according to analytical equilibrium ultracentrifugation studies (James et al., 1997), could be very important in converting PrPc into the prionogenic state through tertiary and quaternary structural changes (Fig. 4). Such an assembly process may be necessary to partially or almost completely unfold PrPc to form the prionogenic intermediate as in the conversion of transthyretin to amyloid fibrils or in the conversion of the lysozyme variants into amyloid respectively (Colon and Kelly, 1991, 1992; Kelly, 1996-1998; Sunde et al., 1997; Torrent et al., 2004). However, while these mechanisms are proposed to produce a PrPSc fibrillar structure similar to amyloid, in fact little is known about the structural details of PrPSc other than that it is richer in  $\beta$ -sheet structure than PrPc (Lansbury, 1992; Kelly, 1997; Prusiner, 1996, 1997).

### Kinetic intermediate

A study by Apetri and Surewicz (2002) provided evidence that the prion protein folds into its native state via a rate-limiting, three-state mechanism involving a monomeric intermediate (Fig. 4). This early intermediate appears to be relatively compact and especially stable under acidic conditions. In addition to its role in normal prion protein folding, the folding intermediate is also likely to be of major importance in the PrPc $\rightarrow$ PrPSc conversion.

The partially folded PrP intermediate is more stable than the fully unfolded protein. This, combined with a relatively high hydrophobicity and aggregation propensity typical of folding intermediates, renders the intermediate state of PrP a better candidate than the unfolded state as a direct monomeric precursor of PrPSc. The role of a folding intermediate in the PrP conversion is in line with the finding that the transition of the recombinant prion protein to a scrapie-like form is strongly promoted in the presence of relatively low concentrations of urea, i.e. under conditions that would increase the population of an intermediate state (Morillas et al., 2001). In contrast, conditions favoring the native state (no denaturant), or those that shift equilibrium toward the fully unfolded state (high concentration of urea), are not conducive to the conversion reaction (Morillas et al., 2001). It should also be noted that the *in vitro* transition of the recombinant PrP to a scrapie-like form appears to be especially effective at low pH (Swietnicki et al., 1997; Hornemann and Glockshuber, 1998). This correlates well with the observation that acidic pH stabilizes the intermediate during the prion protein folding reaction. The PrPc $\rightarrow$ PrPSc conversion in mildly acidic conditions has implications for prion disease pathogenesis since it is reported that this conversion may take place in acidic compartments of the cell (Caughey et al., 1991a,b).

### Amyloid fibril formation

The reason for the toxicity of PrPSc is unknown. Recent *in vitro* evidence provides a clue since high-pressure treatment can trigger formation of  $\beta$ -sheet-rich, protease-resistant, insoluble prion protein structures known as amyloid aggregates (Torrent et al., 2004). At a low protein concentration range and pressures greater than 450 MPa, a metastable intermediate structure, probably a soluble oligomer, is formed (Torrent et al., 2003). At a higher protein concentration (typically 2 mg/mL), the intermediate undergoes further conformational changes and aggregates irreversibly, with the hydrophobic parts of the prion protein becoming water exposed. The protein part undergoing this structural change is probably the region containing residues 90-167, which encompasses helix 1 and the flexible unstructured N-terminal part of the molecule. It appears that high pressure does not completely unfold PrP, but instead induces a misfolded conformation containing water-exposed hydrophobic domains. At a sufficiently high protein concentration (>2 mg/mL) intermolecular collapse of these domains eventually provokes protein aggregation (Torrent et al., 2004).

Fluorescence and electron microscopy, suggests that the aggregates, formed after transient high pressure treatment and decompression, can be classified as pre-amyloid structures with a strongly increased  $\beta$ -sheet content with respect to the native form, and an increased resistance to proteolysis (similarly to the infectious PrPSc form). It is therefore possible that the pre-amyloid form contributes to pathogenesis or is itself infectious (Torrent et al., 2004).

Different proteins do not however, follow the same unfolding pathways (Balny et al., 2002), resulting in different unfolded states which, in some cases, have the tendency to aggregate. Amyloid propagation is normally highly sequence specific. In PrP, this specificity leads to the "species barrier" phenomenon, which obstructs or slows down transmission (Scott et al., 1993; Telling et al., 1995; Gabizon and Taraboulos 1997; Raymond et al., 1997; Baskakov, 2004). Accordingly, a specific pattern of molecular interactions, rather than nonspecific interactions, play a role in the formation of amyloid structures. It has been demonstrated by Van Eldik et al., (1989) that side-chain hydrogen bonds and aromatic stacking play an important role in the stabilization of amyloid structures. They suggested that stacking interactions and/or stabilized hydrogen bonds between newly formed  $\beta$ -sheet strands may contribute energetically as well as directionally in the assembly of well-packed amyloid structures. More research is required to establish the presence and the role of these structures in TSE related neurodegenerative diseases.

### Alternate allelic forms of PrP affect amyloid formation and disease susceptibility

The human PrP gene (*PRNP*) has two common

allelic forms that encode either methionine or valine at codon 129. This polymorphism modulates disease susceptibility and the clinico-pathological phenotypes in sporadic and acquired prion diseases (Collinge et al., 1991; Palmer et al., 1991; Brown et al., 2001; Mead et al., 2001) and may affect age of onset (Baker et al., 1991; Cervenakova et al., 1998; Parchi et al., 1999). All tested cases of variant CJD, to date, have been homozygous for codon 129-MetMet which is in contrast to an overall prevalence of 37% for this genotype in Caucasian populations, indicating a strong genetic risk factor. It is, however, possible that cases with an alternative codon 129 genotype may occur in the future as variations at this locus may influence incubation period (Parchi et al., 1999).

The molecular mechanisms by which the effect of this polymorphism is mediated remain unclear (Baskakov et al., 2005). Residue 129 is within the first  $\beta$ -strand (residues 128–131) in human PrP and might be a 'nucleation site' for a conformational transition from PrPc to PrPSc involving the loops connecting the  $\beta$ -sheet to the first helix (Riek et al., 1996, 1997). The folding, dynamics and stability of the physiological,  $\alpha$ -helix-rich form of recombinant PrP are not affected by codon 129 polymorphism. In contrast, the misfolding pathway leading to the formation of  $\beta$ -sheet-rich, oligomer is favoured by the presence of methionine, compared with valine, at position 129. An alternative folding pathway, of amyloid formation, is favoured by the valine 129 allelomorph, forming amyloid fibres with a considerably shorter lag phase than the methionine 129 allelomorph whether under spontaneous conditions or when seeded with pre-formed amyloid fibres. Taken together, these studies demonstrate that the effect of the codon 129 polymorphism depends on the specific misfolding pathway and on the initial conformation of the protein. The inverse propensities of the two allelomorphs to misfold as shown *in vitro* through the alternative oligomeric and amyloidogenic pathways could explain some aspects of prion diseases linked to this polymorphism such as age at onset and disease incubation time (Fasman 1998; Santini et al., 2003; Baskakov et al., 2005; Tahiri-Alaoui and James, 2005).

The codon 129 polymorphism may also influence the clinical phenotype (including age of onset and illness duration) of genetic prion diseases – ie diseases arising from a mutation in the *PrNP* gene. Most notably, the D178N mutation gives rise to a clinical picture of genetic CJD when associated with 129-Val on the mutant allele and yet results in FFI when associated with 129-Met.

The converse propensities of the 129-Met and 129-Val allelomorphs to fold into  $\beta$ -oligomer and amyloid forms *in vitro*, respectively, is highly intriguing, given the effect of the polymorphism on disease susceptibility *in vivo*. The differences in the misfolding behaviour between 129-Met and 129-Val could form the basis of human TSEs, particularly sporadic CJDs, that are associated with codon 129 variations such as age at

onset of the disease and incubation time (Laplanche et al., 1994; Parchi et al., 1999; Schulz-Schaeffer et al., 1996; Windl et al., 1996; Alperovitch et al., 1999; Hauw et al., 2000). Reports mainly suggest that the age at onset is lower and the disease duration longer in 129-Val cases. This effect appears to be replicated in animal models of human disease: two out of three transgenic mice expressing human PrP 129-Val showed a shorter incubation period (Hill et al., 1997) as compared with transgenic mice expressing human PrP Met129 (Asante et al., 2002) when challenged with a matching genotype inocula.

Of concern are the findings in transgenic studies that a large proportion of infected animals develop sub-clinical disease (Asante et al., 2002; Wadsworth et al., 2004). Taken together with results from a large prevalence study in humans (Hilton et al., 2004) which suggests the presence of subclinical disease, it is possible that these individuals could act as a reservoir of carriers in the population and potentially cause further cases of secondary transmission which could result in vCJD persisting in the population at low levels for many years.

## Conclusion

Although the cellular prion protein is remarkably well conserved in mammals, discerning the function(s) of this small protein has proved challenging. Indeed, PrPc is a case study in protein structural anomalies. There may now be sufficient experimental 'fragments' to begin assembling the larger picture of PrPc function, and to understand the origins and pathogenesis of prion disorders. This, along with developments in immunotherapy, gene therapy and proteomics, may allow design of intervention strategies to halt the progression of prion diseases.

## References

- Aguzzi A., Montrasio F. and Kaeser P.S. (2001). Prions: health scare and biological challenge. *Nature Rev. Mol. Cell Biol.* 2, 118-126.
- Alperovitch A., Zerr I., Pocchiari M., Mitrova E., de Pedro Cuesta J., Hegyi I., Collins S., Kretzschmar H., van Duijn C. and Will R.G. (1999). Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. *Lancet* 353, 1673-1674.
- Apetri A.C. and Surewicz W.K. (2002). Kinetic intermediate in the folding of Human Prion Protein. *J. Biol. Chem.* 277, 44589-44592.
- Asante E.A., Linehan J.M., Desbruslais M., Joiner S., Gowland I., Wood A.L., Welch J., Hill A.F., Lloyd S.E., Wadsworth J.D. and Collinge J. (2002). BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. *EMBO J.* 21, 6358-6366.
- Baker H.E., Poulter M., Crow T.J., Frith C.D., Lofthouse R. and Ridley R.M. (1991). Aminoacid polymorphism in human prion protein and age at death in inherited prion disease. *Lancet* 337, 1286.
- Balhy C., Masson P. and Heremans K. (2002). High-pressure effects on biological macromolecules: from structural changes to alteration of cellular processes. *Biochim. Biophys. Acta* 1595, 3-10.

*Prion protein misfolding and Creutzfeldt-Jakob disease (CJD)*

- Baskakov I.V. (2004). Autocatalytic conversion of recombinant prion proteins displays a species barrier. *J. Biol. Chem.* 279, 7671-7677.
- Baskakov I.V., Disterer P., Breydo L., Shaw M., Gill A., James W. and Tahiri-Alaoui A. (2005). The presence of valine at residue 129 in human prion protein accelerates amyloid formation. *FEBS Lett.* 579, 2589-2596.
- Basler K., Oesch B., Scott M., Westaway D., Wälchli M., Groth D.F., McKinley M.P., Prusiner S.B. and Weissmann G. (1986). Scrapie and cellular PrP isoforms are encoded by the same chromosomal gene. *Cell* 46, 417-428.
- Baybutt H. and Manson J. (1997). Characterisation of two promoters for prion protein (PrP) gene expression in neuronal cells. *Gene* 184, 125-131.
- Belay E. and Schonberger L. (2002). Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy. *Clin. Lab. Med.* 22, 849-862.
- Brandner S., Isenmann S., Raeber A., Fischer M., Sailer A., Kobayashi Y., Marino S., Weissmann C. and Aguzzi A. (1996a). Normal host prion protein necessary for scrapie-induced neurotoxicity. *Nature* 379, 339-343.
- Brandner S., Raeber A., Sailer A., Blattler T., Fischer M., Weissmann C. and Aguzzi A. (1996b). Normal host prion protein (PrP<sup>C</sup>) is required for scrapie spread within the central nervous system. *Proc. Natl. Acad. Sci. USA* 93, 13148-13151.
- Brown P., Will R.G., Bradley R., Asher D.M. and Detwiler L. (2001). Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. *Emerg. Infect. Dis.* 7, 6-16.
- Brown D.R., Schmidt B. and Kretschmar H.A. (1998). Effects of copper on survival of prion protein knockout neurones and glia. *J. Neurochem.* 70, 1686-1693.
- Castilla J., Saa P., Hetz C. and Soto C. (2005). In vitro generation of infectious scrapie prions. *Cell* 121, 195-206.
- Caughey B.W., Dong A., Bhat K.S., Ernst D., Hayes S.F. and Caughey W.S. (1991a). Secondary structure analysis of the scrapie-associated protein PrP 27-30 in water by infrared spectroscopy. *Biochemistry* 30, 7672-7680.
- Caughey B., Raymond G.J., Ernst D. and Race R.E. (1991b). N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. *J. Virol.* 65, 6597-6603.
- Cervenakova L., Goldfarb L.G., Garruto R., Lee H.S., Gajdusek D.C. and Brown P. (1998). Phenotype-genotype studies in kuru: implications for new variant Creutzfeldt-Jakob disease. *Proc. Natl. Acad. Sci. USA* 95, 13239-13241.
- Collinge J., Palmer M.S. and Dryden A.J. (1991). Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. *Lancet* 337, 1441-1442.
- Collinge J., Whittington M.A., Sidle K.C., Smith C.J., Palmer M.S., Clarke A.R. and Jefferys J.G. (1994). Prion protein is necessary for normal synaptic function. *Nature* 370, 295-297.
- Colon W. and Kelly J.W. (1991). Transthyretin acid induced denaturation is sufficient for amyloid fibril formation in vivo. Applications of enzyme biotechnology. Kelly J.W. and Balwin T.O. (eds). Plenum. New York. pp 99-108.
- Colon W. and Kelly J.W. (1992). Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. *Biochemistry* 31, 8654-8660.
- Fasman G.D. (1998). Protein conformational prediction. *Trends Biochem. Sci.* 14, 295-299.
- Gabizon R. and Taraboulos A. (1997). Of mice and (mad) cows transgenic mice help to understand prions. *Trends Genet.* 13, 264-269.
- Gabizon R., McKinley M.P., Groth D. and Prusiner S.B. (1988). Immunoaffinity purification and neutralization of scrapie prion infectivity. *Proc. Natl. Acad. Sci. USA* 85, 6617-6621.
- Gasset M., Baldwin M.A., Fletterick R.J. and Prusiner S.B. (1993). Perturbation of the secondary structure of the scrapie prion protein under conditions that alter infectivity. *Proc. Natl. Acad. Sci. USA* 90, 10962-10966.
- Gasset M., Baldwin M.A., Lloyd D.H., Gabriel J., Holtzman D.M., Cohen F., Fletterick R. and Prusiner S.B. (1992). Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. *Proc. Natl. Acad. Sci. USA* 89, 10940-10944.
- Hauw J.J., Sazdovitch V., Laplanche J.L., Peoc'h K., Kopp N., Kemeny J., Privat N., Delasnerie-Laupretre N., Brandel J.P., Deslys J.P., Dormont D. and Alperovitch A. (2000). Neuropathologic variants of sporadic Creutzfeldt-Jakob disease and codon 129 of PrP gene. *Neurology* 54, 1641-1646.
- Herrmann L.M. and Caughey B. (1998). The importance of the disulfide bond in prion protein conversion. *NeuroReport* 9, 2457-2461.
- Hill A.F., Desbruslais M., Joiner S., Sidle K.C., Gowland I., Collinge J., Doey L.J. and Lantos P. (1997). The same prion strain causes vCJD and BSE. *Nature* 389, 448-450.
- Hilton D.A. (2006). Pathogenesis and prevalence of variant Creutzfeldt-Jakob disease. *J. Pathol.* 208, 134-141.
- Hilton D.A., Ghani A.C., Conyers L., Edwards P., McCordle L., Ritchie D., Penney M., Hegazy D. and Ironside J.W. (2004). Prevalence of lymphoreticular prion protein accumulation in UK tissue samples. *J. Pathol.* 203, 733-739.
- Horiuchi M., Priola S.A., Chabry J. and Caughey B. (2000). Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. *Proc. Natl. Acad. Sci. USA* 97, 5836-5841.
- Horiuchi M. and Caughey B. (1999). Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. *EMBO J.* 18, 3193-3203.
- Hornemann S. and Glockshuber R. (1998). A scrapie-like unfolding intermediate of the prion protein domain PrP(121-231) induced by acidic pH. *Proc. Natl. Acad. Sci. USA* 95, 6010-6014.
- Huang Z., Gabriel M.A., Baldwin M.A., Fletterick R.J., Prusiner S.B. and Cohen F.E. (1994). Proposed three-dimensional structure for the cellular prion protein. *Proc. Natl. Acad. Sci. USA* 91, 7139-7143.
- Ironside J.W. (1998). Neuropathologic findings in new variant CJD and experimental transmission of BSE. *FEMS Immunol. Med. Microbiol.* 21, 91-95.
- James T.L., Liu H., Ulyanov N.B., Farr-Jones, S., Zhang, H., Donne, D.G., Kaneko K., Groth D., Mehlhorn I., Prusiner S.B. and Cohen F.E. (1997). Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform. *Proc. Natl. Acad. Sci. USA* 94, 10086-10091.
- Jarrett J.T. and Lansbury P.T. Jr (1993). Seeding 'one-dimensional crystallization' of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? *Cell* 73, 1055-1058.
- Jefferys J.G., Empson R.M., Whittington M.A. and Prusiner S.B. (1994). Scrapieinfection of transgenic mice leads to network and intrinsic dysfunction of cortical and hippocampal neurones. *Neurobiol. Dis.* 1, 25-30.
- Kahana E., Alter M., Braham J. and Sofer D. (1974). Creutzfeldt-Jakob

- disease: focus among Libyan Jews in Israel. *Science* 183, 90-91.
- Kapitonov V. and Jurka J. (1996). The age of Alu subfamilies. *J. Mol. Evol.* 42, 59-65.
- Kelly J.W. (1996). Alternative conformations of amyloidogenic proteins govern their behavior. *Curr. Opin. Struct. Biol.* 6, 11-17.
- Kelly J.W. (1997). Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. *Structure* 5, 595-600.
- Kelly J.W. (1998). The environmental dependency of protein folding best explains prion and amyloid diseases. *Proc. Natl. Acad. Sci. USA* 95, 930-932.
- Knight R.S. and Will R.G. (2004). Prion diseases. *J. Neurol. Neurosurg. Psychiatry* 75, 36-42.
- Kocisko D.A., Come J.H., Priola S.A., Chesebro B., Raymond G.J., Lansbury P.T. and Caughey B. (1994). Cell-free formation of protease-resistant prion protein. *Nature* 370, 471-474.
- Kretzschmar H.A., Prusiner S.B., Stowring L.E., and DeArmond S.J. (1986). Scrapie prion proteins are synthesized in neurons. *Am. J. Pathol.* 122, 1-5.
- Lansbury P.T. (1992). In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. *Biochemistry* 31, 6865-6870.
- Laplanche J.L., Delasnerie-Laupretre N., Brandel J.P., Chatelain J., Beaudry P., Alperovitch A. and Launay J.M. (1994). Molecular genetics of prion diseases in France. French research group on epidemiology of human spongiform encephalopathies. *Neurology* 44, 2347-2351.
- Lee I.Y., Westaway D., Smit A.F.A., Wang K., Seto J., Chen L., Acharya C., Ankener M., Baskin D., Cooper C., Yao H., Prusiner S.B. and Hood L.E. (1998). Complete genomic sequence and analysis of the prion protein gene region from three mammalian species. *Genome Res.* 8, 1022-1037.
- Li G. and Bolton D.C. (1997). A novel hamster prion protein mRNA contains an extra exon: Increased expression in scrapie. *Brain Res.* 751, 265-274.
- Ma J., Wollmann R. and Lindquist S. (2002). Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. *Science* 298, 1781-1785.
- Mahal S.P., Asante E.A., Antoniou M. and Collinge J. (2001). Isolation and functional characterisation of the promoter region of the human prion protein gene. *Gene* 268, 105-114.
- Manson J.C., Hope J., Clarke A.R., Johnston A., Black C. and MacLeod N. (1995). PrP gene dosage and long term potentiation. *Neurodegeneration* 4, 113-114.
- Masters C.L., Harris J.O., Gajdusek D.C., Gibbs C.J. Jr, Bernoulli C. and Asher D.M. (1979). Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. *Ann. Neurol.* 5, 177-188.
- Mead S., Mahal S.P., Beck J., Campbell T., Farrall M., Fisher E. and Collinge J. (2001). Sporadic—but not variant—Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP Exon 1. *Am. J. Hum. Genet.* 69, 1225-1235.
- Morillas M., Vanik D.L. and Surewicz W.K. (2001). On the mechanism of alpha-helix to beta-sheet transition in the recombinant prion protein. *Biochemistry* 40, 6982-6987.
- Muramoto T., Scott M., Cohen F.E. and Prusiner S.B. (1996). Recombinant scrapie-like prion protein of 106 amino acids is soluble. *Proc. Natl. Acad. Sci. USA* 93, 15457-15462.
- Palmer M.S., Dryden A.J., Hughes J.T. and Collinge J. (1991). Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. *Nature* 352, 340-342.
- Parchi P., Giese A., Capellari S., Brown P., Schulz-Schaeffer W., Windl O., Zerr I., Budka H., Kopp N., Piccardo P., Poser S., Rojiani A., Streichemberger N., Julien J., Vital C., Ghetti B., Gambetti P. and Kretzschmar H. (1999). Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. *Ann. Neurol.* 46, 224-233.
- Pekari K. and Schmidt R.R. (2003). A variable concept for the preparation of branched glycosyl phosphatidyl inositol anchors. *J. Org. Chem.* 68, 1295-1308.
- Prusiner S.B. (1996). Molecular biology and pathogenesis of prion diseases. *Trends Biochem. Sci.* 21, 482-487.
- Prusiner S.B. (1997). Prion diseases and the BSE crisis. *Science* 278, 245-251.
- Prusiner S.B. (1998). Prions. *Proc. Natl. Acad. Sci. USA* 95, 13363-13383.
- Puckett C., Concannon P., Casey C. and Hood L. (1991). Genomic structure of the human prion protein gene. *Am. J. Hum. Genet.* 49, 320-329.
- Raymond G.J., Hope J., Kocisko D.A., Priola S.A., Raymond L.D., Bossers A., Ironside J., Will R.G., Chen S.G., Petersen R.B., Gambetti P., Rubenstein R., Smits M.A., Lansbury P.T. Jr and Caughey B. (1997). Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. *Nature* 388, 285-288.
- Riek R., Hornemann S., Wider G., Billeter M., Glockshuber R. and Wuthrich K. (1996). NMR structure of the mouse prion protein domain PrP(121-321). *Nature* 382, 180-182.
- Riek R., Hornemann S., Wider G., Glockshuber R. and Wuthrich K. (1997). NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). *FEBS Lett.* 413, 282-288.
- Santini S., Claude J.B., Audic S. and Derreumaux P. (2003). Impact of the tail and mutations G131V and M129V on prion protein flexibility. *Proteins* 51, 258-265.
- Schulz-Schaeffer W.J., Giese A., Windl O. and Kretzschmar H.A. (1996). Polymorphism at codon 129 of the prion protein gene determines cerebellar pathology in Creutzfeldt-Jakob disease. *Clin. Neuropathol.* 15, 353-357.
- Scott M., Groth D., Foster D., Torchia M., Yang S.L., DeArmond S.J. and Prusiner S.B. (1993). Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. *Cell* 73, 979-988.
- Smit A.F.A. (1996). The origin of interspersed repeats in the human genome. *Curr. Opin. Genet. Dev.* 6, 743-748.
- Smit A.F., Tóth G., Riggs A.D. and Jurka J. (1996). Ancestral, mammalian-wide subfamilies of LINE1 repetitive sequences. *J. Mol. Biol.* 246, 401-417.
- Smit A.F.A. and Riggs A.D. (1995). Tiggers and DNA transposon fossils in the human genome. *Proc. Natl. Acad. Sci. USA* 93, 1443-1448.
- Stahl N., Bladwin M.A., Burlingame A.L. and Prusiner S.B. (1990). Identification of glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. *Biochemistry* 29, 8879-8884.
- Stahl N., Borchelt D.R., Hsiao K. and Prusiner S.B. (1987). Scrapie prion protein contains a phosphatidylinositol glycolipid. *Cell* 51, 229-240.
- Sunde D.R., Bellott M., Robinson V., Hutchinson C.V., Fraser W.L., Hawkins P.E., Dobson P.N., Radford C.M., Blake S.E. and Pepys M.B. (1997). *Nature* 385, 787-793.

*Prion protein misfolding and Creutzfeldt-Jakob disease (CJD)*

- Swietnicki W., Petersen R., Gambetti P. and Surewicz W.K. (1997). pH-dependent stability and conformation of the recombinant human prion protein PrP(90-231). *J. Biol. Chem.* 272, 27517-27520.
- Tahiri-Alaoui A. and James W. (2005). Rapid formation of amyloid from {alpha}-monomeric recombinant human PrP in vitro. *Protein Sci.* 14, 942-947.
- Telling G.C., Scott M., Mastrianni J., Gabizon R., Torchia M., Cohen F.E., DeArmond S.J. and Prusiner S.B. (1995). Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. *Cell* 83, 79-90.
- Torrent J., Alvarez-Martinez M.T., Heitz F., Liautard J.P., Balny C. and Lange R. (2003). Alternative prion structural changes revealed by high pressure. *Biochemistry* 42, 1318-1325.
- Torrent J., Alvarez-Martinez M.T., Harricane M.C., Heitz F., Liautard J.P., Balny C. and Lange R. (2004). High pressure induces scrapie-like prion protein misfolding and amyloid fibril formation. *Biochemistry* 43, 7162-7170.
- Van Eldik R., Asano T. and Le Noble W.J. (1989). Activation and reaction volume in solution 2. *Chem. Rev.* 89, 549-688.
- Wadsworth J.D., Asante E.A., Desbruslais M., Linehan J.M., Joiner S., Gowland I., Welch J., Stone L., Lloyd S.E., Hill A.F., Brandner S. and Collinge J. (2004). Human prion protein with valine 129 prevents expression of variant CJD phenotype. *Science* 306, 1793-1796.
- Welker E., Wedemeyer W.J. and Scheraga H.A. (2001). A role for intermolecular disulfide bonds in prion diseases? *Proc. Natl. Acad. Sci. USA* 98, 4334-4336.
- Will R.G., Alpers M.P., Dormont D. and Schonberger L.B. (2004). Infectious and sporadic prion diseases. In: *Prion biology and diseases*. Prusiner S.B. (ed). Cold Spring Harbor Laboratory Press. New York. pp 629-671.
- Windl O., Dempster M., Estibeiro J.P., Lathe R., de Silva R., Esmonde T., Will R., Springbett A., Campbell T.A., Sidle K.C., Palmer M.S. and Collinge J. (1996). Genetic basis of Creutzfeldt-Jakob disease in the United Kingdom: a systematic analysis of predisposing mutations and allelic variation in the PRNP gene. *Hum. Genet.* 98, 259-264.
- Yoshimoto J., Iinuma T., Ishiguro N., Horiuchi M., Imamura M. and Shinagawa M. (1992). Comparative sequence analysis and expression of bovine PrP gene in mouse L-929 cells. *Virus Genes* 6, 343-356.
- Zaborowski A. (2004). Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies, Part II. *Psychiatr. Pol.* 38, 297-309.

Accepted April 2, 2007